Harmony Biosciences

112 articles about Harmony Biosciences

• HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 34th ANNUAL HEALTHCARE CONFERENCE

  11/9/2022

  Harmony Biosciences Holdings, Inc. today announced that Harmony's management will participate in a fireside chat and host investor meetings at the upcoming Piper Sandler 34th Annual Healthcare Conference.

• HARMONY BIOSCIENCES ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT STUDY EVALUATING PITOLISANT FOR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH PRADER-WILLI SYNDROME

  11/1/2022

  Topline data show positive signal in treating excessive daytime sleepiness.

• Harmony Biosciences Reports Third Quarter 2022 Financial Results and Business Updates

  11/1/2022

  Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today reported financial results and business updates for the quarter ended September 30, 2022.

• HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2022 FINANCIAL RESULTS ON NOVEMBER 1, 2022

  10/18/2022

  Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (NASDAQ: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will report third quarter 2022 financial results on Tuesday, November 1, 2022.

• HARMONY BIOSCIENCES ANNOUNCES 2022 FUNDING RECIPIENTS OF PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD PROGRAMS

  9/22/2022

  Harmony Biosciences Holdings, Inc. today announced on the fourth annual World Narcolepsy Day, the funding recipients of its Patients at the Heart  and Prorgress at the Heart Award Programs.

• HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

  8/17/2022

  Harmony Biosciences Holdings, Inc. today announced that Harmony's management will participate in the following upcoming investor conference.

• Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates

  8/2/2022

  Harmony Biosciences Holdings, Inc. today reported financial results and business updates for the quarter ended June 30, 2022.

• HARMONY BIOSCIENCES ANNOUNCES DATE OF SECOND QUARTER 2022 FINANCIAL RESULTS

  7/19/2022

   Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it will issue a press release on the Company's second quarter 2022 financial results on Tuesday, August 2, 2022.

• Harmony Biosciences Reports First Quarter 2022 Financial Results and Business Updates

  5/3/2022

  Harmony Biosciences Holdings, Inc. today reported financial results and business updates for the quarter ended March 31, 2022.

• 

  Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

  5/2/2022

  A roundup of last week's top clinical trial updates and news.

• HARMONY BIOSCIENCES INITIATES PHASE 3 TRIAL OF PITOLISANT IN ADULT PATIENTS WITH IDIOPATHIC HYPERSOMNIA

  4/27/2022

  Harmony Biosciences Holdings, Inc. today announced the initiation of its Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study. 

• Harmony Biosciences Opens Applications For 2022 Progress At The Heart Program

  4/7/2022

  Harmony Biosciences Holdings, Inc. is now accepting applications for the second annual Progress at the Heart program, which funds innovative programs that address disparities, injustice, and inequities in the rare neurological disease and sleep disorder communities.

• Harmony Biosciences To Participate In 21st Annual Needham Virtual Healthcare Conference

  4/4/2022

  Harmony Biosciences Holdings, Inc. announced that Harmony's President and CEO, John C. Jacobs, will present a company update and host investor meetings at the upcoming 21st Annual Needham Virtual Healthcare Conference.

• HARMONY BIOSCIENCES ANNOUNCES APPLICATIONS OPEN MARCH 18 FOR 2022 PATIENTS AT THE HEART PROGRAM

  3/17/2022

  Harmony Biosciences Holdings, Inc. today announced applications open on "World Sleep Day", Friday, March 18, 2022, for its Patients at the Heart Program.

• Harmony Biosciences To Participate In Two Investor Conferences In March 2022

  3/9/2022

  Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that its executive leaders will participate in the following upcoming virtual conferences.

• Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

  2/28/2022

  Harmony Biosciences Holdings, Inc. today reported financial results and business updates for the fourth quarter and full year ended December 31, 2021.

• Harmony Biosciences to Participate in 40th Annual J.P. Morgan Healthcare Conference

  1/5/2022

  Harmony Biosciences Holdings, Inc. today announced that Harmony's President and CEO, John C. Jacobs will present a company update and host investor meetings at the upcoming 40th Annual J.P. Morgan Healthcare Conference.

• Harmony Biosciences to be Added to the Nasdaq Biotech Index

  12/17/2021

  Harmony Biosciences Holdings, Inc. today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI).

• Harmony Biosciences To Participate In Two Investor Conferences In November

  11/11/2021

  Harmony Biosciences Holdings, Inc. today announced that Harmony's President and CEO, John C. Jacobs , will participate in fireside chats and host investor meetings at the following upcoming virtual conferences:

• Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates

  11/9/2021

  Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates